Literature DB >> 15710593

Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.

Francesca Patriarca, Simonetta Prosdocimo, Valentina Tomadini, Annarosa Vasciaveo, Benedetto Bruno, Renato Fanin.   

Abstract

We report the successful use of bortezomib to treat a patient with multiple myeloma (MM) who had extramedullary relapse (paraspinal and thoracic masses and multiple cranial nerve palsy) after autologous and non-myeloablative allogeneic hematopoietic stem cell transplantation (HSCT).

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15710593

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  18 in total

Review 1.  Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention.

Authors:  Fuling Zhou; Shan Meng; Huanjin Song; François X Claret
Journal:  Blood Rev       Date:  2013-09-02       Impact factor: 8.250

Review 2.  Extramedullary multiple myeloma.

Authors:  Manisha Bhutani; David M Foureau; Shebli Atrash; Peter M Voorhees; Saad Z Usmani
Journal:  Leukemia       Date:  2019-11-27       Impact factor: 11.528

Review 3.  How We Manage Patients with Plasmacytomas.

Authors:  Despina Fotiou; Meletios A Dimopoulos; Efstathios Kastritis
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

4.  Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.

Authors:  Marcello Rotta; Barry E Storer; Firoozeh Sahebi; Judith A Shizuru; Benedetto Bruno; Thoralf Lange; Edward D Agura; Peter A McSweeney; Michael A Pulsipher; Parameswaran Hari; Richard T Maziarz; Thomas R Chauncey; Frederick R Appelbaum; Mohamed L Sorror; William Bensinger; Brenda M Sandmaier; Rainer F Storb; David G Maloney
Journal:  Blood       Date:  2008-11-17       Impact factor: 22.113

5.  Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma.

Authors:  Adrian Alegre; Isabel Vicuña; Beatriz Aguado
Journal:  Clin Med Insights Oncol       Date:  2011-12-06

6.  Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents resistance.

Authors:  Xiaoyan Qu; Lijuan Chen; Hairong Qiu; Hua Lu; Hanxin Wu; Hongxia Qiu; Peng Liu; Rui Guo; Jianyong Li
Journal:  Biomed Res Int       Date:  2015-04-23       Impact factor: 3.411

7.  Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma.

Authors:  L Vincent; P Ceballos; C Plassot; J C Méniane; P Quittet; R Navarro; C Cyteval; V Szablewski; Z Y Lu; T Kanouni; J Moreaux; G Cartron; B Klein; N Fegueux
Journal:  Blood Cancer J       Date:  2015-08-21       Impact factor: 11.037

8.  Extramedullary relapse of IgA-lambda myeloma after recent bortezomib therapy: a case report.

Authors:  Deirdre F Waterhouse; Geraldine A Moloney; Fatma S Gargoum; Peter S Hayden; Tom O'Gorman
Journal:  Cases J       Date:  2009-09-14

9.  Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies.

Authors:  Lourdes Farre; Gabriela Sanz; Neus Ruiz-Xivillé; Manuel Castro de Moura; Juan Francisco Martin-Tejera; Samuel Gonçalves-Ribeiro; Maria Martinez-Iniesta; Monica Calaf; Jose Luis Mosquera; José Ignacio Martín-Subero; Isabel Granada; Manel Esteller; Eva Domingo-Domenech; Fina Climent; Alberto Villanueva; Anna Sureda
Journal:  Dis Model Mech       Date:  2021-07-15       Impact factor: 5.758

10.  Recurrent plasmacytomas after allografting in a patient with multiple myeloma.

Authors:  Allen N Stawis; Diane Maennle; Moreno Festuccia; Zia Uddin; Benedetto Bruno
Journal:  Case Rep Med       Date:  2012-12-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.